A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have added about 7.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

Sage Chief Medical Officer Laura Gault, M.D., Ph.D., is stepping down to pursue a new opportunity effective March 21, the ...

New leadership at Seattle-area companies including Starbucks, Avanade, Tune Therapeutics, Umoja Biopharma, Siteimprove and ...

Scotiabank analyst George Farmer maintained a Hold rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of ...

Having achieved "Awardable” status for three separate applications, Sage can now explore developing a utility-scale ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against the other psychedelic stocks. In contrast to drugs like cocaine or marijuana ...

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality." One class of hallucinogenic substances that can produce unusual ...

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality." One class of hallucinogenic substances that can produce unusual states ...